NantHealth, Inc. [NH] Stock Forecast

Q: What is NantHealth, Inc. stock symbol ?

NantHealth, Inc. is a US stock, located in Morrisville of Nc and trading under the symbol NH

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NH Stock Summary

Earnings are expected to rise 19.86% next year

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($17.41M)

NH has less than 1 year of cash runway

Top 10 Correlated ETFs

NH

Top 10 Correlated Stocks

NH

In the News

07:04 26 Mar 2023 NH

NantHealth, Inc. (NH) Q3 2022 Earnings Call Transcript

NantHealth, Inc. (NASDAQ:NH ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Ron Louks - Chief Operating Officer Bob Petrou - Chief Financial Officer Conference Call Participants Robert Jaffe Welcome everyone and thank you for joining us today to discuss NantHealth's 2022 Third Quarter Financial Results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

04:50 26 Mar 2023 NH

NantHealth to Report 2022 Third-Quarter Financial Results and Host Conference Call on Thursday, November 3

MORRISVILLE, N.C.

06:45 26 Mar 2023 NH

NantHealth, Inc. (NH) Management on Q2 2022 Results - Earnings Call Transcript

NantHealth, Inc. (NASDAQ:NH ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Ron Louks - Chief Operating Officer Bob Petrou - Chief Financial Officer Robert Jaffe Welcome, everyone, and thank you for joining us today to discuss NantHealth's 2022 second quarter financial results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

03:30 26 Mar 2023 NH

NantHealth's (NH) Management on Q1 2022 Results - Earnings Call Transcript

NantHealth, Inc. (NASDAQ:NH ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Robert Jaffe – Investor Relations Ron Louks – Chief Operating Officer Bob Petrou – Chief Financial Officer Conference Call Participants Robert Jaffe Welcome, everyone, and thank you for joining us today to discuss NantHealth's 2022 First Quarter Financial Results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

10:16 26 Mar 2023 NH

NantHealth, Inc. (NH) Q4 2021 Results - Earnings Call Transcript

08:46 26 Mar 2023 NH

NantHealth, Inc. (NH) Reports Q4 Loss, Tops Revenue Estimates

NantHealth, Inc. (NH) delivered earnings and revenue surprises of -11.11% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

10:05 26 Mar 2023 NH

NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue Estimates

NantHealth, Inc. (NH) delivered earnings and revenue surprises of -25.00% and -18.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

08:00 26 Mar 2023 NH

NantHealth's Chief Medical Officer to Educate on Advancing Equity in Cancer Care at the Oncology Clinical Pathways Congress 2021

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that Dr. Tiffany Avery, Chief Medical Officer, was selected to present a continuing education session at the Oncology Clinical Pathways Congress 2021. Dr. Avery's session, titled Utilizing Pathways to Advance Equity in Cancer Care, will take place virtually on Friday, October 1, 2021, and cover how clinical p

10:50 26 Mar 2023 NH

NantHealth, Inc. (NH) Management on Q2 2021 Results - Earnings Call Transcript

08:32 26 Mar 2023 NH

NantHealth, Inc. (NH) Reports Q2 Loss, Lags Revenue Estimates

NantHealth, Inc. (NH) delivered earnings and revenue surprises of 20.00% and -5.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NH Financial details

Company Rating

Neutral

Market Cap

17.41M

Income

-58.82M

Revenue

65.53M

Book val./share

-26.11

Cash/share

0.08

Dividend

Dividend %

Employees

326

Optionable

Shortable

Yes

Earnings

22 Mar 2023

P/E

-0.3

Forward P/E

PEG

-30.93

P/S

0.27

P/B

-0.09

P/C

28.25

P/FCF

-0.49

Quick Ratio

0.23

Current Ratio

0.36

Debt / Equity

-1.8

LT Debt / Equity

-1.26

EPS (TTM)

-7.64

EPS next Y

EPS next Q

-0.09

EPS this Y

0.32%

EPS next Y

EPS next 5Y

-95.42%

EPS last 5Y

-19.4%

Revenue last 5Y

-6.29%

Revenue Q/Q

0.81%

EPS Q/Q

9.15%

SMA20

-31.58%

SMA50

-40.06%

SMA100

-59.92%

Inst Own

3.5%

Inst Trans

-0.59%

ROA

-37%

ROE

32%

ROC

-0.39%

Gross Margin

57%

Oper. Margin

-77%

Profit Margin

-90%

Payout

Shs Outstand

7.7M

Shs Float

2.01M

Target Price

52W Range

1.57-11.985

52W High

-79.45%

52W Low

+126%

RSI

43.77

Rel Volume

0.1

Avg Volume

17.93K

Volume

1.72K

Perf Week

7.11%

Perf Month

-41.45%

Perf Quarter

-38.83%

Perf Half Y

-63.83%

Beta

1.86847

Volatility

0.25%, 0.51%

Prev Close

-4.64%

Price

2.26

Change

7.62%

NH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	11.14	12.29	13.04	9.89	8.23
Net income per share	-22.51	-26.4	-8.53	-7.63	-7.66
Operating cash flow per share	-10.43	-4.07	-1.19	-2.28	-3.64
Free cash flow per share	-12.18	-5.52	-1.82	-3.05	-4.31
Cash per share	7.92	2.52	0.71	3.08	3.82
Book value per share	24.84	0.39	-7.77	-15.11	-21.29
Tangible book value per share	1.19	-24.43	-30.57	-36.23	-39.34
Share holders equity per share	24.84	0.39	-7.77	-15.11	-21.29
Interest debt per share	27.19	29.9	30.51	2.63	35.62
Market cap	356.05M	59.41M	113.66M	358.38M	120.43M
Enterprise value	489.85M	241.58M	314.84M	335.87M	347.91M
P/E ratio	-2.03	-0.31	-1.81	-6.35	-2.07
Price to sales ratio	4.11	0.66	1.18	4.9	1.92
POCF ratio	-4.39	-2	-12.97	-21.26	-4.35
PFCF ratio	-3.76	-1.48	-8.51	-15.91	-3.67
P/B Ratio	1.84	20.99	-1.99	-3.21	-0.74
PTB ratio	1.84	20.99	-1.99	-3.21	-0.74
EV to sales	5.65	2.7	3.28	4.59	5.55
Enterprise value over EBITDA	-3.68	-1.55	-14.01	-16.77	-12.44
EV to operating cash flow	-6.04	-8.15	-35.92	-19.93	-12.56
EV to free cash flow	-5.17	-6.01	-23.57	-14.91	-10.62
Earnings yield	-0.49	-3.23	-0.55	-0.16	-0.48
Free cash flow yield	-0.27	-0.68	-0.12	-0.06	-0.27
Debt to equity	1.32	100.14	-5.66	-2.79	-2.22
Debt to assets	0.57	0.99	1.21	1.64	1.82
Net debt to EBITDA	-1	-1.17	-8.95	1.12	-8.14
Current ratio	2.28	1.08	0.66	0.25	1.41
Interest coverage	-4.2	-2.96	-1.71	-1.37	-2.82
Income quality	0.46	0.15	0.14	0.3	0.48
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.87	0.79	0.64	0.66	0
Research and developement to revenue	0.39	0.23	0.2	0.24	0.31
Intangibles to total assets	0.41	0.63	0.63	0.77	0.69
Capex to operating cash flow	0.17	0.36	0.52	0.34	0.18
Capex to revenue	-0.16	-0.12	-0.05	-0.08	-0.08
Capex to depreciation	-0.49	-0.47	-0.21	-0.34	-0.32
Stock based compensation to revenue	0.05	0.06	0.03	0.04	0.06
Graham number	112.17	15.2	38.61	50.94	60.55
ROIC	-0.21	-0.2	-0.12	-0.19	-0.3
Return on tangible assets	-0.66	-1.82	-0.64	-1.29	-0.96
Graham Net	-23.74	-34.73	-40.33	-38.72	-42.84
Working capital	46.03M	2.91M	-19.59M	-94.16M	11.47M
Tangible asset value	9.25M	-177.8M	-224.91M	-267.99M	-299.36M
Net current asset value	-174M	-244.06M	-285.71M	-281.09M	-320.41M
Invested capital	1.01	70.81	-3.61	0	-1.58
Average receivables	13.35M	14.18M	22.33M	15.82M	4.79M
Average payables	4.94M	2.41M	2.8M	4.54M	4.16M
Average inventory	1.53M	667.5K	647K	399K	0
Days sales outstanding	50.85	66.47	107.9	16.33	36.8
Days payables outstanding	27.81	13.6	37.53	32.56	42.06
Days of inventory on hand	7.38	4.09	7.58	0	0
Receivables turnover	7.18	5.49	3.38	22.36	9.92
Payables turnover	13.12	26.83	9.72	11.21	8.68
Inventory turnover	49.49	89.25	48.15	0	0
ROE	-0.91	-67.87	1.1	0.5	0.36
Capex per share	-1.75	-1.45	-0.62	-0.77	-0.67

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	1.86	2.08	2.13	2.14	2.16
Net income per share	-1.41	-2.17	-2.07	-1.62	-1.77
Operating cash flow per share	-0.74	-0.69	-1.43	-1.19	-0.65
Free cash flow per share	-0.96	-0.81	-1.59	-1.4	-0.82
Cash per share	5.92	3.78	2.09	0.74	0.08
Book value per share	-19.11	-21.04	-22.93	-24.42	-26.11
Tangible book value per share	-37.28	-38.89	-40.48	-41.67	-43.08
Share holders equity per share	-19.11	-21.04	-22.93	-24.42	-26.11
Interest debt per share	35.51	33.79	33.85	33.78	33.86
Market cap	185.54M	121.81M	87.06M	48.25M	28.46M
Enterprise value	409.29M	349.3M	328.23M	299.3M	285.18M
P/E ratio	-4.28	-1.82	-1.36	-0.96	-0.52
Price to sales ratio	12.97	7.6	5.32	2.92	1.71
POCF ratio	-32.55	-22.97	-7.88	-5.28	-5.66
PFCF ratio	-25.06	-19.43	-7.11	-4.47	-4.5
P/B Ratio	-1.26	-0.75	-0.49	-0.26	-0.14
PTB ratio	-1.26	-0.75	-0.49	-0.26	-0.14
EV to sales	28.61	21.79	20.05	18.14	17.15
Enterprise value over EBITDA	-122.1	-38.94	-38.76	-57.71	-46.44
EV to operating cash flow	-71.8	-65.86	-29.71	-32.73	-56.76
EV to free cash flow	-55.27	-55.72	-26.79	-27.7	-45.13
Earnings yield	-0.06	-0.14	-0.18	-0.26	-0.48
Free cash flow yield	-0.04	-0.05	-0.14	-0.22	-0.22
Debt to equity	-2.48	-2.22	-2.03	-1.89	-1.8
Debt to assets	1.68	1.82	1.97	2.13	2.25
Net debt to EBITDA	-66.75	-25.36	-28.48	-48.41	-41.8
Current ratio	1.64	1.41	1.04	0.63	0.36
Interest coverage	-3.1	-3.35	-3.62	-3.38	-4.03
Income quality	0.53	0.32	0.69	0.73	0.37
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.32	0.32	0.35	0.36	0.38
Intangibles to total assets	0.64	0.69	0.74	0.8	0.81
Capex to operating cash flow	0.3	0.18	0.11	0.18	0.26
Capex to revenue	-0.12	-0.06	-0.07	-0.1	-0.08
Capex to depreciation	-0.44	-0.23	-0.3	-0.43	-0.32
Stock based compensation to revenue	0.06	0.08	0.08	0.08	0.05
Graham number	24.63	32.06	32.69	29.87	32.27
ROIC	-0.09	-0.09	-0.09	-0.08	-0.09
Return on tangible assets	-0.14	-0.28	-0.34	-0.37	-0.45
Graham Net	-40.89	-42.35	-43.86	-44.8	-46.24
Working capital	22.23M	11.47M	1.12M	-8.73M	-21.44M
Tangible asset value	-286.4M	-299.36M	-311.74M	-321.01M	-331.84M
Net current asset value	-307.36M	-320.41M	-331.87M	-340.12M	-349.93M
Invested capital	-1.83	-1.58	-1.46	-1.36	-1.28
Average receivables	5.68M	6.17M	5.92M	5.53M	6.28M
Average payables	2.2M	2.64M	4.25M	5.07M	5.53M
Average inventory	0	0	0	0	0
Days sales outstanding	37.87	35.46	30.4	30.14	38.01
Days payables outstanding	27.47	41.63	66.29	59.38	80.75
Days of inventory on hand	0	0	0	0	0
Receivables turnover	2.38	2.54	2.96	2.99	2.37
Payables turnover	3.28	2.16	1.36	1.52	1.11
Inventory turnover	0	0	0	0	0
ROE	0.07	0.1	0.09	0.07	0.07
Capex per share	-0.22	-0.13	-0.16	-0.22	-0.17

NH Frequently Asked Questions

What is NantHealth, Inc. stock symbol ?

NantHealth, Inc. is a US stock , located in Morrisville of Nc and trading under the symbol NH

What is NantHealth, Inc. stock quote today ?

NantHealth, Inc. stock price is $2.26 today.

Is NantHealth, Inc. stock public?

Yes, NantHealth, Inc. is a publicly traded company.

Something similar

Top by Market Cap

ABEC.DE

Company Profile

Volume Average 17.93K
Market Capitalization 17.41M
Employee 326
CEO Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc.
Headquarters Morrisville,NC,US
IPO Date 2016-06-02
Website https://nanthealth.com

NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers Quadris, a data solution that includes multi-data analysis, reporting, and professional services. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Morrisville, North Carolina. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.